Russell Investments Group Ltd. Decreases Stock Holdings in BioNTech SE (NASDAQ:BNTX)

Russell Investments Group Ltd. decreased its holdings in shares of BioNTech SE (NASDAQ:BNTX) by 64.5% during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 4,599 shares of the company’s stock after selling 8,361 shares during the quarter. Russell Investments Group Ltd.’s holdings in BioNTech were worth $573,000 as of its most recent SEC filing.

Other hedge funds also recently bought and sold shares of the company. Eagle Bay Advisors LLC purchased a new stake in BioNTech during the second quarter valued at $33,000. Resurgent Financial Advisors LLC purchased a new stake in BioNTech during the fourth quarter valued at $47,000. Signaturefd LLC raised its stake in BioNTech by 18,750.0% during the first quarter. Signaturefd LLC now owns 377 shares of the company’s stock valued at $47,000 after purchasing an additional 375 shares in the last quarter. EverSource Wealth Advisors LLC purchased a new stake in BioNTech during the fourth quarter valued at $58,000. Finally, Heritage Wealth Management LLC raised its stake in BioNTech by 100.8% during the fourth quarter. Heritage Wealth Management LLC now owns 474 shares of the company’s stock valued at $71,000 after purchasing an additional 238 shares in the last quarter. Hedge funds and other institutional investors own 15.52% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts recently issued reports on the stock. Redburn Partners raised shares of BioNTech from a “neutral” rating to a “buy” rating and upped their price target for the company from $165.00 to $170.00 in a research note on Wednesday, May 17th. Deutsche Bank Aktiengesellschaft reduced their target price on shares of BioNTech from $135.00 to $120.00 in a research note on Thursday, May 18th. HC Wainwright reissued a “buy” rating and issued a $180.00 target price on shares of BioNTech in a research note on Monday, August 28th. Morgan Stanley reduced their target price on shares of BioNTech from $119.00 to $116.00 and set an “equal weight” rating on the stock in a research note on Tuesday, August 8th. Finally, HSBC initiated coverage on shares of BioNTech in a research note on Friday, July 14th. They issued a “buy” rating and a $124.00 target price on the stock. Five equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. Based on data from MarketBeat, BioNTech currently has an average rating of “Moderate Buy” and a consensus target price of $158.69.

BioNTech Stock Performance

Shares of BioNTech stock opened at $121.75 on Friday. The firm has a market capitalization of $29.34 billion, a P/E ratio of 6.82 and a beta of 0.18. The company has a quick ratio of 10.32, a current ratio of 10.56 and a debt-to-equity ratio of 0.01. The company has a 50 day moving average price of $109.93 and a 200 day moving average price of $116.31. BioNTech SE has a 52 week low of $95.50 and a 52 week high of $188.99.

BioNTech (NASDAQ:BNTX) last announced its quarterly earnings data on Monday, August 7th. The company reported ($0.79) EPS for the quarter, beating the consensus estimate of ($0.83) by $0.04. The firm had revenue of $167.70 million during the quarter, compared to analyst estimates of $628.13 million. BioNTech had a net margin of 47.37% and a return on equity of 21.46%. BioNTech’s revenue was down 94.8% on a year-over-year basis. During the same period last year, the firm posted $7.31 EPS. Sell-side analysts expect that BioNTech SE will post 6.12 EPS for the current year.

About BioNTech

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.